A diminished generic and biosimilars trade group could have negative consequences for its members: Only eight of its 23 member companies employ in-house lobbyists in Washington, outside firms or both.
The Association for Accessible Medicines, the generic drugmakers' industry group, laid off its top lobbyist and two other executives, and some of the association's K Street firms could be next.
Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and.